BnH Research
BnH Research is dedicated to developing therapeutics for chronic conditions, focusing on CNS disorders such as Alzheimer's Disease, PTSD, Addiction, Autism, and Stroke. The company aims to address unmet medical needs through innovative drug discovery and research services, emphasizing brain plasticity and neuroregeneration.
Industries
Nr. of Employees
small (1-50)
BnH Research
A. 209, Samsong Techno Valley, 140 Tongil-ro, Deogyang-gu, Goyang-si, Gyeonggi-do, Republic of Korea
Products
Preclinical Alzheimer's disease drug candidate (BDNF–GluN2B pathway modulator)
A preclinical small-molecule candidate developed to enhance cortical plasticity via upregulation of BDNF and modulation of GluN2B, evaluated in APP mouse models with synaptic and behavioral endpoints.
Preclinical PTSD drug candidate
A development-stage therapeutic candidate evaluated in rodent PTSD models and behavioral assays to address limitations of current antidepressant/SSRI therapies.
Preclinical development-disorder (autism-related) program
Preclinical program focused on pharmacological approaches to reduce behavioral signs associated with developmental disorders (e.g., repetitive behaviors, aggression, attention issues), evaluated in relevant animal models.
Preclinical Alzheimer's disease drug candidate (BDNF–GluN2B pathway modulator)
A preclinical small-molecule candidate developed to enhance cortical plasticity via upregulation of BDNF and modulation of GluN2B, evaluated in APP mouse models with synaptic and behavioral endpoints.
Preclinical PTSD drug candidate
A development-stage therapeutic candidate evaluated in rodent PTSD models and behavioral assays to address limitations of current antidepressant/SSRI therapies.
Preclinical development-disorder (autism-related) program
Preclinical program focused on pharmacological approaches to reduce behavioral signs associated with developmental disorders (e.g., repetitive behaviors, aggression, attention issues), evaluated in relevant animal models.
Services
On-site electrophysiology assays including single-cell and brain-slice patch-clamp recordings for ion channel and synaptic function assessment to support lead selection and mechanism studies.
Design and execution of behavioral assays for cognition, anxiety/depression, locomotion, decision-making, and motor coordination with automated video tracking.
Cardiac functional assays including Langendorff isolated heart experiments and cardiomyocyte electrophysiology to evaluate cardiac efficacy and safety parameters.
Provision of optimized experimental protocols and consulting for study design across brain, cardiovascular, and pain/itch targets to support lead selection and optimization.
Collaborative screening and target identification using third-party AI platforms to accelerate discovery of candidate compounds.
Facilitated access to contract manufacturing and GLP-compliant testing through external provider agreements to support preclinical and regulatory activities.
On-site electrophysiology assays including single-cell and brain-slice patch-clamp recordings for ion channel and synaptic function assessment to support lead selection and mechanism studies.
Design and execution of behavioral assays for cognition, anxiety/depression, locomotion, decision-making, and motor coordination with automated video tracking.
Cardiac functional assays including Langendorff isolated heart experiments and cardiomyocyte electrophysiology to evaluate cardiac efficacy and safety parameters.
Provision of optimized experimental protocols and consulting for study design across brain, cardiovascular, and pain/itch targets to support lead selection and optimization.
Collaborative screening and target identification using third-party AI platforms to accelerate discovery of candidate compounds.
Facilitated access to contract manufacturing and GLP-compliant testing through external provider agreements to support preclinical and regulatory activities.
Expertise Areas
- Preclinical efficacy evaluation
- Electrophysiology and ion channel pharmacology
- Synaptic plasticity and mechanism-of-action research
- Behavioral pharmacology and cognitive phenotyping
Key Technologies
- Patch-clamp electrophysiology
- Brain slice electrophysiology
- In vivo rodent disease models
- Behavioral testing platforms (Morris water maze, fear conditioning, O-maze, etc.)
News & Updates
신경세포 연결망 되살려 자극에 민감하게 반응 자극 치료 효율 극대화하는 ‘뇌 재활치료’ 알츠하이머병·PTSD·자폐증 치료, 뇌 회춘도. 혈관성 치매는 전체 치매 환자의 30% 이상이 될 것으로 추산되지만 아직 치료법이 개발되지 않음.
경구용 GluN2B PAM이 AD 마우스모델에서 대뇌피질 신경가소성을 강화하고 인지능력을 향상시키며, Aβ와 신경염증이 감소하는 연구 결과. 올해 초 1/2a상 IND 제출 계획.
120억 규모 시리즈B 투자 유치로 인지기능증진제 개발 본격화. 대뇌피질의 시냅스 가소성 증가를 통한 인지기능 정상화와 전임상 연구 가속화.
신경세포 연결망 되살려 자극에 민감하게 반응 자극 치료 효율 극대화하는 ‘뇌 재활치료’ 알츠하이머병·PTSD·자폐증 치료, 뇌 회춘도. 혈관성 치매는 전체 치매 환자의 30% 이상이 될 것으로 추산되지만 아직 치료법이 개발되지 않음.
경구용 GluN2B PAM이 AD 마우스모델에서 대뇌피질 신경가소성을 강화하고 인지능력을 향상시키며, Aβ와 신경염증이 감소하는 연구 결과. 올해 초 1/2a상 IND 제출 계획.
120억 규모 시리즈B 투자 유치로 인지기능증진제 개발 본격화. 대뇌피질의 시냅스 가소성 증가를 통한 인지기능 정상화와 전임상 연구 가속화.